Filing Flows › BioXcel Therapeutics (BTAIQ) › Who owns the stock
Who owns BioXcel Therapeutics (BTAIQ) stock
44 funds reported BioXcel Therapeutics (BTAIQ) shares in their latest 13F filings, worth $9.1M in all. The largest holder is Millennium Management LLC ($3.0M). Last quarter 22 funds added to their stakes and 12 cut them.
Largest holders (13F)
| Fund | Shares | Value | Change | Quarter |
|---|---|---|---|---|
| Millennium Management LLC | 2,114,710 | $3.0M | new | 2026-06-30 |
| Oaktree Capital Management LP | 1,380,248 | $1.9M | increase | 2026-06-30 |
| Vanguard Capital Management LLC | 919,545 | $1.3M | increase | 2026-06-30 |
| Vanguard Group | 292,753 | $468K | increase | 2025-12-31 |
| Oaktree Fund Advisors, LLC | 245,585 | $346K | increase | 2026-06-30 |
| Geode Capital Management, LLC | 242,251 | $342K | increase | 2026-06-30 |
| BlackRock | 179,433 | $253K | increase | 2026-06-30 |
| UBS Group AG | 158,065 | $223K | increase | 2026-06-30 |
| Citadel Advisors LLC | 149,220 | $210K | new | 2026-06-30 |
| Vanguard Fiduciary Trust | 136,937 | $193K | increase | 2026-06-30 |
| State Street | 92,118 | $130K | unchanged | 2026-06-30 |
| FMR LLC | 90,300 | $127K | unchanged | 2026-06-30 |
| &Partners | 83,588 | $118K | increase | 2026-06-30 |
| Jones Financial Companies Lllp | 63,139 | $83K | decrease | 2026-06-30 |
| Northern Trust | 56,318 | $79K | increase | 2026-06-30 |
BioXcel Therapeutics' latest quarter
BioXcel Therapeutics, Q2 2026: revenue $182K (+52% year over year), net loss $14.7M, operating cash flow −$6.1M. The chart follows the revenue to costs, profit and cash.
Questions
Who owns the most BTAIQ stock?
By the latest 13F filings: Millennium Management LLC ($3.0M); Oaktree Capital Management LP ($1.9M); Vanguard Capital Management LLC ($1.3M); Vanguard Group ($468K); Oaktree Fund Advisors, LLC ($346K).
What is the short interest in BTAIQ?
1,641,640 shares were sold short at the 2026-10-15 settlement, -16.56% of the float.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.